101 related articles for article (PubMed ID: 32646965)
21. SND1 binds to ERG and promotes tumor growth in genetic mouse models of prostate cancer.
Liao SY; Rudoy D; Frank SB; Phan LT; Klezovitch O; Kwan J; Coleman I; Haffner MC; Li D; Nelson PS; Emili A; Vasioukhin V
Nat Commun; 2023 Nov; 14(1):7435. PubMed ID: 37973913
[TBL] [Abstract][Full Text] [Related]
22. Long Non-Coding RNA Landscape in Prostate Cancer Molecular Subtypes: A Feature Selection Approach.
De Summa S; Palazzo A; Caputo M; Iacobazzi RM; Pilato B; Porcelli L; Tommasi S; Paradiso AV; Azzariti A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672425
[TBL] [Abstract][Full Text] [Related]
23. The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer.
Wang S; Kollipara RK; Humphries CG; Ma SH; Hutchinson R; Li R; Siddiqui J; Tomlins SA; Raj GV; Kittler R
Oncotarget; 2016 Oct; 7(40):64921-64931. PubMed ID: 27626314
[TBL] [Abstract][Full Text] [Related]
24. High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
Weidemann SA; Sauer C; Luebke AM; Möller-Koop C; Steurer S; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Fraune C; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Heumann A
BMC Cancer; 2019 Oct; 19(1):944. PubMed ID: 31606028
[TBL] [Abstract][Full Text] [Related]
25. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer.
Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H
Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199
[No Abstract] [Full Text] [Related]
26. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
[TBL] [Abstract][Full Text] [Related]
27. ETS transcription factor ERG cooperates with histone demethylase KDM4A.
Kim TD; Shin S; Janknecht R
Oncol Rep; 2016 Jun; 35(6):3679-88. PubMed ID: 27109047
[TBL] [Abstract][Full Text] [Related]
28. Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes.
Mao N; Gao D; Hu W; Hieronymus H; Wang S; Lee YS; Lee C; Choi D; Gopalan A; Chen Y; Carver BS
Mol Cancer Ther; 2019 Sep; 18(9):1577-1586. PubMed ID: 31296553
[TBL] [Abstract][Full Text] [Related]
29. Long non-coding RNA FAM66C is associated with clinical progression and promotes cell proliferation by inhibiting proteasome pathway in prostate cancer.
Xie Y; Gu J; Qin Z; Ren Z; Wang Y; Shi H; Chen B
Cell Biochem Funct; 2020 Dec; 38(8):1006-1016. PubMed ID: 32430927
[TBL] [Abstract][Full Text] [Related]
30. CTCF regulates the FoxO signaling pathway to affect the progression of prostate cancer.
Shan Z; Li Y; Yu S; Wu J; Zhang C; Ma Y; Zhuang G; Wang J; Gao Z; Liu D
J Cell Mol Med; 2019 May; 23(5):3130-3139. PubMed ID: 30873749
[TBL] [Abstract][Full Text] [Related]
31. --A high-throughput screen identifies inhibitors of the interaction between the oncogenic transcription factor ERG and the cofactor EWS.
Nicholas TR; Meng J; Greulich BM; Morris TS; Hollenhorst PC
PLoS One; 2020; 15(9):e0238999. PubMed ID: 32915889
[TBL] [Abstract][Full Text] [Related]
32. ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells.
Wang L; Li Y; Yang X; Yuan H; Li X; Qi M; Chang YW; Wang C; Fu W; Yang M; Zhang J; Han B
Prostate; 2014 May; 74(6):647-58. PubMed ID: 24435928
[TBL] [Abstract][Full Text] [Related]
33. AMPK and AKT protein kinases hierarchically phosphorylate the N-terminus of the FOXO1 transcription factor, modulating interactions with 14-3-3 proteins.
Saline M; Badertscher L; Wolter M; Lau R; Gunnarsson A; Jacso T; Norris T; Ottmann C; Snijder A
J Biol Chem; 2019 Aug; 294(35):13106-13116. PubMed ID: 31308176
[TBL] [Abstract][Full Text] [Related]
34. ERG-Mediated Coregulator Complex Formation Maintains Androgen Receptor Signaling in Prostate Cancer.
Shah N; Kesten N; Font-Tello A; Chang MEK; Vadhi R; Lim K; Flory MR; Cejas P; Mohammed H; Long HW; Brown M
Cancer Res; 2020 Nov; 80(21):4612-4619. PubMed ID: 32934023
[TBL] [Abstract][Full Text] [Related]
35. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells.
Gupta S; Iljin K; Sara H; Mpindi JP; Mirtti T; Vainio P; Rantala J; Alanen K; Nees M; Kallioniemi O
Cancer Res; 2010 Sep; 70(17):6735-45. PubMed ID: 20713528
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers.
Burdelski C; Fitzner M; Hube-Magg C; Kluth M; Heumann A; Simon R; Krech T; Clauditz T; Büscheck F; Steurer S; Wittmer C; Hinsch A; Luebke AM; Jacobsen F; Minner S; Tsourlakis MC; Beyer B; Steuber T; Thederan I; Sauter G; Izbicki J; Schlomm T; Wilczak W
Neoplasia; 2017 Apr; 19(4):279-287. PubMed ID: 28282546
[TBL] [Abstract][Full Text] [Related]
37. p16 upregulation is linked to poor prognosis in ERG negative prostate cancer.
Burdelski C; Dieckmann T; Heumann A; Hube-Magg C; Kluth M; Beyer B; Steuber T; Pompe R; Graefen M; Simon R; Minner S; Tsourlakis MC; Koop C; Izbicki J; Sauter G; Krech T; Schlomm T; Wilczak W; Lebok P
Tumour Biol; 2016 Sep; 37(9):12655-12663. PubMed ID: 27444279
[TBL] [Abstract][Full Text] [Related]
38. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
[TBL] [Abstract][Full Text] [Related]
39. ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients.
Almami A; Hegazy SA; Nabbi A; Alshalalfa M; Salman A; Abou-Ouf H; Riabowol K; Bismar TA
Tumour Biol; 2016 Jul; 37(7):9731-8. PubMed ID: 26803516
[TBL] [Abstract][Full Text] [Related]
40. Rearranged ERG confers robustness to prostate cancer cells by subverting the function of p53.
Kaczorowski A; Tolstov Y; Falkenstein M; Vasioukhin V; Prigge ES; Geisler C; Kippenberger M; Nientiedt C; Ratz L; Kuryshev V; Herpel E; Kristiansen G; Sültmann H; Stenzinger A; Doeberitz MVK; Hohenfellner M; Duensing A; Duensing S
Urol Oncol; 2020 Sep; 38(9):736.e1-736.e10. PubMed ID: 32674955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
